Open Targets announced this morning that Pfizer has joined the partnership.
“Pfizer joining Open Targets as our next partner is a real external vote of confidence in the work we are doing,” says Ian Dunham, director of Open Targets.
“Pfizer’s emphasis on the use of human genetics and genomics in drug discovery is a perfect fit for the partnership. They will immediately benefit from access to all our published and as yet unpublished data that Open Targets members have a first right to review. I look forward to working together.”
Read the full press release, and celebrate with us on Twitter and LinkedIn!